Pooled 5-FU Population PK Model Supports Lean Mass and Model-Informed Dosing
This individual patient data meta-analysis builds a generalizable population pharmacokinetic model for intravenous 5-fluorouracil and offers simulated evidence that model-informed precision dosing outperforms conventional therapeutic drug monitoring for reaching target exposure.
📅 Journal publication: Jun 12, 2026·Last updated: Jul 20, 2026
5-fluorouracilfluoropyrimidinescolorectal cancerpopulation pharmacokineticsmodel-informed precision dosingtherapeutic drug monitoringlean body massNONMEMIPD meta-analysisoncologyPharmacokinetics / TDM
Understanding the pharmacokinetics of 5-fluorouracil is crucial for optimizing dose and therapeutic efficacy, especially in colorectal cancer treatment. A model-based approach using lean body mass and model-informed precision dosing improves target attainment significantly better than traditional TDM methods. The study suggests a shift towards lean body mass-based dosing and model-informed strategies, which could reduce variability seen with body-surface area dosing. Utilizing lean body mass and model-informed precision dosing can enhance therapeutic outcomes in 5-fluorouracil therapy.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Briki M, Thoueille P, Joerger M, Chatelut E, Sterle M, Schmitt A, Wagner AD, Buclin T, Carrara S, Guidi M
Citation:Briki M, Thoueille P, Joerger M, et al. Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics. Cancer chemotherapy and pharmacology. 2026;96(1). doi:10.1007/s00280-026-04885-x